To assess the feasibility and safety of stereotactic ablative body radiotherapy (SABR) for renal cell carcinoma (RCC) in patients unsuitable for surgery. Secondary objectives were to assess oncological and functional outcomes.
Introduction
Renal cell carcinoma is the 8 th most common cancer worldwide [1] and continues to increase in incidence and lethality. According to the American Cancer Society, kidney cancer incidence rates increased by 4.1% per year in men and 3.3% per year in women between 2004 and 2008 [2] . Surgery is the standard of care for primary RCC; however, many patients are in an older age group [3] and have associated medical comorbidities that may preclude them from extirpative therapies. Patients undergoing partial (PN) or radical nephrectomy (RN) experience postoperative nephron loss, which may result in de novo chronic kidney disease or advancement of pre-existing renal dysfunction [4] . Non-surgical definitive treatment options for this population of patients are limited. Radiofrequency ablation (RFA) and cryotherapy are two common thermal ablation techniques that have specific limitations. They are typically limited to small renal masses and are generally restricted to lesions located away from the ureter and vascular structures because of the risk of heat sink effects, stricture and/or fistula development [5] . With larger tumours there is a significant risk of haemorrhage, which can require major intervention to control. Both of these techniques are invasive, adding to complication risk and issues with managing anticoagulative medications.
By contrast, stereotactic ablative body radiotherapy (SABR) is a non-invasive treatment option for patients deemed unsuitable for surgical intervention. SABR is delivered to patients whilst fully awake and in a single or few outpatient treatment sessions. SABR is well established in the treatment of cancers in the lung, liver and spine. Whilst the approach is still emerging in the kidney, it is not technically limited by tumour proximity to central pelvic-calyceal structures or to small renal masses [6] ; however, there is a paucity of prospective data to support the routine adoption of SABR for primary inoperable RCC [7] . In this context we conducted a prospective clinical trial of SABR for this disease setting. The primary purpose of the present study was to assess the feasibility and safety of this approach using conventional linear accelerators without fiducial marker insertion, an approach readily translatable to radiotherapy departments worldwide.
Materials and Methods

Patient Population
This was an institutional ethics board-approved single institutional prospective clinical trial (clinicaltrials.gov ID NCT01676428) conducted at the Peter MacCallum Cancer Centre. All patients signed informed consent. Eligible patients were enrolled between 2012 and 2014 and were aged >18 years, had Eastern Cooperative Oncology Group (ECOG) performance scores of 0-2 inclusive and had a single lesion within the target kidney. Patients were medically inoperable, were in the high-risk group for surgery (because of likelihood of post-surgical dialysis) or refused surgery. Patients were excluded when receiving systemic therapy prior to or concurrent with SABR, or when having previously received high-dose radiotherapy to the upper abdomen. Biopsy confirmation was attempted in all patients when possible. Patients with small renal masses (T1a disease) were evaluated closely for the need for treatment factoring for existing comorbidites; these patients had documented growth on serial imaging, and/or were symptomatic with haematuria or pain. Multidisciplinary tumour board consensus was required before active intervention was recommended. Bloods were taken for haematology (including neutrophil and lymphocyte count) and electrolyes (including creatinine) at baseline and at each clinical visit.
Study Objectives
The primary objective was to assess the feasibility of treatment, as defined by successfully delivering the treatment plan as prescribed and achieving the nominated dose constraints. Secondary objectives were to assess: (1) treatment-related adverse events; (2) freedom from local progression; (3) freedom from distant progression; and (4) overall survival. A further exploratory objective was to identify possible predictors of change in tumour size after 1 year of SABR.
Study Protocol
Trial investigations occurred every 3 months after treatment with data close-out after all patients completed a minimum of 12 months' potential follow-up. Investigations included serum urea and electrolytes and estimated GFR (eGFR) using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula calculations, CT of the chest and abdomen and clinical review with adverse event reporting. All Response Evaluation Criteria In Solid Tumors v1.1 (RECIST) [8] tumour measurements were performed by a single experienced radiologist (T.T.).
For primary RCCs <5 cm in size (maximum dimension) a single treatment of 26 Gy was delivered. For RCCs of ≥ 5 cm (maximum dimension) 42 Gy in three fractions was delivered on non-consecutive days. All treatments were delivered on conventional c-arm linear accelerators, either Varian Truebeam STx or Trilogy (Varian, Palo Alto, CA, USA). All patients were immobilized using an Elekta Bodyfix dual vacuum device (Medical Intelligence, Schwabmünchen, Germany). Radiotherapy treatment delivery techniques have been previously described in detail [9] . The motion encompassing internal target volume was constructed using four-dimensional CT simulation. A 5-mm expansion was given to derive the planning target volume (PTV). The peak dose within the internal target volume was typically 125% of the prescribed dose, with target coverage of the PTV being 95-99% by the prescription isodose.
Statistical Methods
Patient demographics, baseline characteristics and treatment details are described using descriptive statistics. Ninety-five percent exact two-sided CIs were used to assess the primary objective of feasibility. Treatment-related toxicities were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Toxicities were reported separately for the acute period (up to 90 days from SABR treatment) and late period (beyond 90 days from SABR treatment). Freedom from local progression, freedom from distant progression and overall survival were estimated using the Kaplan-Meier method with 624 © 2017 The Authors BJU International © 2017 BJU International corresponding 95% CIs. Freedom from local progression, freedom from distant progression and overall survival rates were calculated from the date of first SABR treatment. Local progression was defined using RECIST v1.1. The percentage change in tumour size (maximum diameter in axial and transverse directions) and volume from baseline was calculated for each CT assessment. Linear regression was used to assess candidate prognostic variables (histological grade, target volume, dose and neutrophil:lymphocyte ratio) for change in tumour size from baseline to 1 year after SABR.
The proportion of patients who developed new-onset chronic kidney disease (CKD), as defined by eGFR < 60 mL/min, was described. Estimate of change in eGFR in 1 year with 95% CI was provided from a linear mixed model with time as a fixed effect and patient as a random effect. This process was repeated for the subset of patients with/without pre-existing CKD and by number of risk factors for CKD. Average GFR loss from baseline to 1 and 2 years was estimated with 95% CIs.
Results
In the 2-year accrual period 37 eligible patients signed informed consent. These patient characteristics are shown in Table 1 . T1a disease accounted for 35% of cases, with T1b in 62% and T2a in 3% of cases. Histological confirmation was achieved in 92% of kidneys (n = 34). Of these cases, tumour necrosis in the pathological specimen was noted in 33 (97%), and no cases demonstrated sarcomatoid differentiation. Medical risk factors for CKD included diabetes in 14 (38%), hypertension in 24 (65%) and cardiovascular disease in 19 patients (51%). The Charlson comorbidity score was ≥6 in 28 patients (76%), with 11 patients referred because they were at technically high risk of post-surgical dialysis (30%) with a complex tumour in a dominant functioning kidney. Only one patient in the cohort refused surgery as the reason for enrolment (Charlson comorbidity score 1).
Of the 37 patients who fulfilled eligibility criteria, 33 patients received all study treatments to 34 primary RCCs, resulting in a feasibility rate of 89% (95% CI 73-94). Of the 4/37 patients for which treatment was not delivered, one patient with a pulmonary embolus prior to SABR died after an international flight and two could not meet planned dose constraints. One further patient completed only two of three planned fractions because of social difficulties. Acute and late treatment-related toxicities are shown in Table 2 . One patient (3%) had a treatment-related grade 3 toxicity (fatigue), 26 (78%) reported grade 1-2 treatment-related toxicity as worst grade and six patients (18%) reported no treatment-related side effects. There was no treatment-related mortality, and no grade 4 toxicities were recorded. Oncological outcomes are shown in Figs 1 and 2. The freedom from local progression rates at 1 and 2 years were100%. One patient progressed locally with concurrent distant progression at 28 months after treatment. The freedom from distant progression rates at 1 and 2 years were 97% (95% CI 91-100) and 89% (95% CI 78-100), respectively. The 1-and 2-year overall survival rates were 100% and 92% (95% CI 81-100), respectively. At last followup, four patients had partial responses and 28 had stable disease, as defined by RECIST criteria. Objective tumour size reduction at 1 year was observed in 61% of RCCs after SABR. In the univariate analysis describing % change in tumour size from baseline to 1 year (Table 3) , only a lower neutrophil:lymphocyte ratio was significantly associated with tumour shrinkage (r 2 = 0.45, P < 0.001). A representative image of tumour shrinkage after therapy is shown in Fig. 3 .
The baseline mean (range) eGFR was 55 (18-97) mL/ min. At 1 year the eGFR was reduced by 11 mL/min (95% CI 6-17), and in the subset of nine patients who were assessed at 2 years, there was a similar reduction from baseline by 11 mL/min (95% CI [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Whilst the change in eGFR was statistically significant at 1 year (P < 0.001) using linear mixed models, the slopes of change in eGFR in patients with pre-existing CKD were not different from patients without pre-existing CKD (difference in slopes of À2.1 mL/min (95% CI À5.3 to 1.1; P = 0.196). The slopes by the number of risk factors for CKD was also not statistically significant (P = 0.536).
Discussion
The present study has demonstrated the safety and efficacy of a conventional linear accelerator based technique for the treatment of primary inoperable RCC. The majority (65%) of tumours treated were large renal masses (>4 cm). We observed grade 3 toxicity rates of 3% (transient fatigue) and no grade 4-5 toxicities. Importantly, most patients sustained only transient minor side effects (78%) or no treatmentrelated side effects (18%). Freedom from local progression at 2 years was 100%, with freedom from distant progression and overall survival being 89% and 92%, respectively. These results compare favourably with the existing largely retrospective literature suggesting local control rates ranging between 84 and 100%, with similarly low rates of associated toxicity [10] . A recent prospective phase I trial of 19 patients and a prospective series of 29 patients with primary RCC [11, 12] corroborate the findings of infrequent treatmentrelated side effects (< 5% grade 3+ toxicities). Most of the existing literature is from groups using the Cyberknife TM (Accuray, Sunnyvale, CA, USA), a specialized robotic stereotactic radiotherapy delivery system. This system necessitates the insertion of fiducial markers for tumour tracking, an intervention that is invasive and associated with the risk of tumour haemorrhage. Importantly, our results were derived using conventional radiotherapy linear accelerators that are ubiquitous in modern radiotherapy departments worldwide, supporting the generalizability of our results internationally.
The majority (65%) of patients treated in our cohort had primary RCC > 4 cm in size. A major advantage of SABR over thermal ablation is the capacity to treat larger masses, as RFA and microwave ablation (MWA) are typically limited to the treatment of smaller small renal masses (< 4 cm). Whilst cryotherapy has the capacity to treat larger tumours, both complication rate and efficacy appear to be reduced. A multivariable analysis of outcomes in 99 patients undergoing laparoscopic cryoablation from the Netherlands determined that whilst lesion complexity did not prognosticate for risk of complications, tumour size >3.5 cm did [13] . Tumour control also appears to correlate to size, with a study in 124 patients from Washington University [14] of percutaneous cryoablation reporting a 2-year disease-free survival rate of 85%, with tumour size >3 cm being predictive of recurrence on multivariable analysis. Overall, one meta-analysis [15] reported a similar proportion of clinical efficacy for cryoablation at 89% vs RFA at 90%, whilst another [16] suggested better local tumour control of 94.8% after cryoablation compared with 87.1% after RFA. These rates are similar to those in the present series (despite the treatment of T1b and T2 disease) and to other literature on SABR for primary RCC [10] . Importantly SABR has a protocol and is thus not dependent on technician experience or learning curve, increasingly the likelihood of reproducibility outside of major academic centres.
An important consideration with regard to ablative interventions for primary RCC is the ability to conserve nephrons and renal function. At the last recorded clinical visit, up to 3 years after SABR, no patient required renal replacement therapy. Both SABR and thermal ablative techniques affect a rim of surrounding normal kidney [17, 18] . Meaningful comparisons are particularly challenging, as resultant renal dysfunction is proportional to tumour size and volume of ablation zones [19] . Most series of thermal ablation report outcomes from only small renal masses of typical average sizes, ranging from 2 to 3 cm in diameter, with very limited prospectively collected renal function outcomes. In one prospective study of 102 patients randomized to MWA vs PN, the mean tumour sizes were 3.1 and 2.8 cm, respectively. The mean eGFR for the MWA arm dropped by 7 mL/min from a baseline value of 130 mL/min, and dropped by 25 mL/min from a baseline value of 113 mL/ min in the PN arm [20] . In a further study of 541 patients randomized between RN and PN [21] , the median tumour size was 3.0 cm. During the first year after surgery, mean eGFR was 52.7 mL/min in the RN arm and 66.8 mL/min in the PN arm. The proportion reaching a postoperative eGFR was <60 mL/min was 85.7% with RN and 64.7% with PN. By comparison, the median tumour size treated in this trial was 4.8 cm, and the mean pre-treatment eGFR was already significantly impaired at 55 mL/min. The average posttreatment reduction was to 44 mL/min, and no patient required dialysis. In the 14 patients with an initial eGFR of >60 mL/min, new-onset eGFR of <60 mL/min occurred in 10 patients (71.4%). Importantly, this proportion of new-onset CKD was similar to that of PN in the surgical series discussed above (64.7%), and lower than that of RN (85.7%) [21] . Our cohort had significant medical risk factors for CKD, including diabetes in 38%, hypertension in 65% and cardiovascular disease in 51% of patients. Thus, whilst it is difficult to compare treatment approaches given the differences in tumour size, patient comorbidities and preexisting renal dysfunction, in the context of the alternative therapeutic interventions of surgery and thermal ablation we observed a similar and clinically acceptable preservation of renal function after SABR, consistent with previous reports [11, 12] .
An exploratory finding of this study was the inverse correlation observed between neutrophil:lymphocyte ratio and tumour response to SABR. Raised levels of circulating neutrophils in peripheral blood is considered to be a biomarker of a chronic inflammatory state within the host, whilst depressed lymphocyte levels are considered to be reflective of a reduced capacity to mount an inflammatory response to cancer [22] . Although it is recognized that SABR is highly effective at RCC control in preclinical [23] and clinical studies [24] , this efficacy may not be solely attributable to higher biological radiation dose. Indeed, it is possible that some of the efficacy of SABR is directly attributable to immune stimulating properties [25] . RCC is a 628 © 2017 The Authors BJU International © 2017 BJU International highly immunogenic tumour that has shown impressive responses to immunotherapy [26] as well as 'abscopal' or outof-field distant tumour responses to radiotherapy with or without immunotherapy [25] . It may be that the association between lower neutrophil:lymphocyte ratio and tumour shrinkage is a correlate of lymphocyte-mediated adaptive immune response in the irradiated primary. This suggests possible utility as a novel and easily accessible predictive biomarker of response to therapy in patients undergoing SABR for primary RCC. This finding warrants further investigation and validation in future studies.
Radiological response assessment after SABR using CT criteria represents several challenges. Post-ablative radiotherapy effects in the tumour and adjacent normal tissues can evolve over years [27] , and in the more common application of SABR for lung tumours, functional imaging with positron emission tomography can detect metabolic responses that long predate any CT apparent morphological changes [28] ; however, positron emission tomography does not have an established role in the context of primary RCC. Presence of tumour cells on biopsy after ablative radiation can also be unreliable, such as in the context of prostate brachytherapy, where positive biopsies can occur up to 2 years post-therapy but do not correlate to biochemical disease control [29] . Whilst residual post-radiation tissue within the treated field is expected, tumour progression on CT imaging is not, and thus progression is typically used as a surrogate for treatment failure.
The present study has several limitations. First and foremost, because this is an early-phase clinical trial, longer-term follow-up is required to establish robust efficacy outcomes in this cohort. Secondly, the treatment of small renal masses may be criticized by some, with expected growth rates of 0.25 cm per year [30] and low metastatic potential [31] . As described the patients in the present study had already demonstrated progression and/or symptoms after initial active surveillance, and treatment was recommended only once comorbidities had been carefully balanced by a multidisciplinary tumour board. Furthermore the vast majority of tumours included in the present study were larger masses indicating the feasibility of SABR in masses not amenable to thermal ablative techniques. Additionally, histological confirmation was not achieved in all cases (8%). Finally, the observed post-treatment decline in GFR was modest but, again, longer-term data would be reassuring in order to evaluate functional outcomes.
In conclusion, SABR for both small and large primary RCC is well tolerated. We observed encouraging cancer control, functional preservation and survival in an inoperable cohort. Baseline neutrophil:lymphocyte ratio may be predictive of immune-mediated response and warrants further investigation. The findings of this study have been used to inform the design of an international phase II clinical trial under the auspices of the TransTasman Radiation Oncology Group (TROG 15.03 FASTRACK, clinicaltrials.gov ID NCT02613819). This study is designed with the purpose of validating the efficacy of our treatment technique in a multiinstitutional setting.
